Psychiatry and Neurology, Neurology · Lutherville, MD
NPI
1881741775
Since 2007
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
2
Medicare group memberships
Hospitals
4
Hospital affiliations
1447 York Rd Ste 508
Lutherville, MD, 21093
Phone (410) 828-4629
Groups this clinician bills Medicare through
Medicare paid, 2024
$4.7M
129,627 services
Medicare patients, 2024
332
Average age 68
Drug cost, 2024
$1.9M
857 prescriptions
Company payments, 2025
$165K
From 29 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Daniel Becker was code J2350 (injection, ocrelizumab, 1 mg), 78,300 times for 76 patients. In total Daniel Becker billed 129,627 services in 51 codes, and Medicare paid $4.7M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-03-18.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J2350 Injection, ocrelizumab, 1 mg | Office | 78,300 | 76 | $45.14 | $3.5M |
| J2329 Injection, ublituximab-xiiy, 1mg | Office | 8,250 | 11 | $51.01 | $421K |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 5,175 | 89 | $0.22 | $1,151 |
| 99215 Office E&M - Established | Office | 393 | 162 | $133.29 | $52K |
| 96413 Chemotherapy Administration | Office | 245 | 108 | $102.69 | $25K |
| 96139 Behavioral Health Services | Office | 228 | 114 | $27.65 | $6,305 |
| 96415 Chemotherapy Administration | Office | 223 | 88 | $22.60 | $5,040 |
| G0453 Continuous intraoperative neurophysiology monitoring, from outside the operating room (remote or nearby), per patient, (attention directed exclusively to one patient) each 15 minutes (list in addition to primary procedure) | Facility | 190 | 18 | $25.90 | $4,921 |
| 95937 Electrical Nerve Conductivity | Facility | 163 | 70 | $27.28 | $4,447 |
| 92133 Computerized Ophthalmic Imaging | Office | 115 | 115 | $28.15 | $3,237 |
| 96132 Behavioral Health Services | Office | 114 | 114 | $98.21 | $11K |
| 96138 Behavioral Health Services | Office | 114 | 114 | $27.55 | $3,141 |
| 96127 Behavioral Health Services | Office | 106 | 106 | $3.73 | $395 |
| 95870 Electrical Nerve Conductivity | Facility | 82 | 41 | $15.64 | $1,282 |
| J2930 Injection, methylprednisolone sodium succinate, up to 125 mg | Office | 75 | 41 | $3.57 | $267 |
By year: 2022 $4.4M for 94,036 services; 2023 $4.6M for 102,596 services; 2024 $4.7M for 129,627 services.
Medicare prescription drug claims, 2024
In 2024, the drug Daniel Becker prescribed most often to Medicare patients was Baclofen, with 148 prescriptions and refills. In total Daniel Becker wrote 857 Medicare prescriptions that cost $1.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Baclofen Generic | 148 | 228 | 26 | $2,304 |
| Dalfampridine Er Dalfampridine | 71 | 85 | Under 11 | $25K |
| Teriflunomide Generic | 65 | 75 | 11 | $147K |
| Gabapentin Generic | 55 | 105 | 12 | $1,365 |
| Aubagio Teriflunomide | 54 | 68 | Under 11 | $628K |
| Copaxone Glatiramer Acetate | 37 | 37 | Under 11 | $227K |
| Zeposia Ozanimod Hydrochloride | 32 | 40 | Under 11 | $369K |
| Modafinil Generic | 27 | 45 | Under 11 | $2,615 |
| Botox Onabotulinumtoxina | 20 | 59 | Under 11 | $41K |
| Armodafinil Generic | 18 | 24 | Under 11 | $2,134 |
| Aimovig Autoinjector Erenumab-Aooe | 18 | 25 | Under 11 | $19K |
| Amitriptyline Hcl Generic | 18 | 24 | Under 11 | $313 |
| Vitamin D2 Ergocalciferol (Vitamin D2) | 17 | 38 | Under 11 | $292 |
| Levetiracetam Generic | 17 | 23 | Under 11 | $292 |
| Tizanidine Hcl Generic | 16 | 48 | Under 11 | $291 |
Brand drugs: 225 claims; generic drugs: 632 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Daniel Becker $165K ($165K in general payments such as food, travel and fees) from 29 companies. The largest payer was Vanda Pharmaceuticals Inc. with $72K.
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. VNDA | 77 | $72K |
| Amgen Inc. AMGN | 46 | $29K |
| Eisai Inc. 4523.T | 44 | $26K |
| TG Therapeutics, Inc. TGTX | 31 | $22K |
| Genzyme Corporation SNY | 9 | $6,193 |
| E.R. Squibb & Sons, L.L.C. BMY | 3 | $5,845 |
| Genentech USA, Inc. ROG.SW | 20 | $665 |
| EMD Serono, Inc. MRK.DE | 11 | $527 |
| Abbvie Inc. ABBV | 39 | $514 |
| Celgene Corporation BMY | 31 | $316 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.